recent
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
nearli
decad
sever
acut
respiratori
syndrom
sar
cov
highlight
import
understand
develop
therapeut
treatment
current
emerg
cov
manuscript
explor
role
cov
infect
host
immun
respons
review
highlight
conserv
motif
requir
interact
partner
well
attenu
mutant
restor
mutant
specif
immun
knockout
importantli
work
also
identifi
number
approach
exploit
understand
therapeut
treatment
data
clearli
illustr
import
activ
cov
infect
pathogenesi
coronavirus
repres
import
human
pathogen
emerg
multipl
time
zoonot
reservoir
past
centuri
becker
et
al
graham
et
al
li
et
al
nichol
et
al
perlman
netland
aftermath
sever
acut
respiratori
syndrom
coronaviru
sarscov
emerg
substanti
effort
made
improv
understand
cov
infect
pathogenesi
order
develop
novel
therapeut
current
futur
cov
mediat
outbreak
perlman
netland
despit
signific
advanc
past
decad
broadli
effect
treatment
sarscov
remain
elus
coupl
recent
emerg
middl
east
respiratori
syndrom
mer
cov
corman
et
al
josset
et
al
virul
strain
porcin
epidem
diarrhea
viru
pedv
huang
et
al
lack
progress
underscor
continu
need
studi
develop
treatment
famili
virus
sarscov
outbreak
progress
comput
model
predict
number
enzymat
function
conserv
viral
polyprotein
includ
conserv
activ
cov
nonstructur
protein
snijder
et
al
unknown
time
subsequ
immun
research
reveal
role
viral
mrna
distinguish
selfnonself
daffi
et
al
zust
et
al
presenc
host
viru
effector
suggest
import
virul
determin
cov
infect
review
examin
interact
partner
activ
well
factor
mediat
host
respons
addit
manuscript
explor
approach
exploit
pathway
therapeut
treatment
current
emerg
diseas
overal
review
seek
updat
current
state
cov
field
possibl
futur
therapeut
base
target
activ
correspond
immun
respons
overcom
host
immun
respons
paramount
success
viral
infect
sinc
immun
respons
predic
recognit
virus
evolv
mean
disrupt
host
sens
either
direct
antagon
pathway
compon
molecular
mimicri
host
process
decroli
et
al
import
exampl
latter
duplic
cap
element
viral
mrna
decroli
et
al
eukaryot
host
util
cap
system
promot
effici
nuclear
export
robust
translat
enhanc
stabil
host
mrna
addit
mrna
cap
structur
also
help
distinguish
selfnonself
rna
lead
initi
host
immun
respons
recent
year
unprotect
nascent
rna
fig
identifi
part
recognit
trigger
host
sensor
molecul
retino
acid
induc
gene
rigi
lead
stream
type
ifn
induct
hornung
et
al
myong
et
al
similarli
ifninduc
protein
tetratricopeptid
repeat
ifit
highli
induc
interferonstimul
gene
isg
also
bind
expos
viral
rna
interf
activ
competit
diamond
pichlmair
et
al
habjan
et
al
triphosph
cleavag
addit
cap
effect
protect
host
mrna
particular
target
fig
howev
unmethyl
ribos
rna
also
identifi
pathogen
associ
molecular
pattern
pamp
recogn
host
sensor
molecul
melanoma
differentiationassoci
protein
well
effector
ifit
famili
absenc
viral
rna
induc
robust
type
ifn
respons
attenu
viral
replic
infect
vitro
vivo
fig
daffi
et
al
zust
et
al
contrast
viral
mrna
maintain
cap
cap
fig
remain
viabl
level
similar
host
mrna
togeth
recognit
moieti
subsequ
host
respons
indic
import
mrna
cap
restrict
barrier
viral
infect
find
also
rais
possibl
cap
activ
may
preferenti
function
defens
mechan
cell
intrins
antivir
effector
suggest
possibl
viral
mrna
preferenti
translat
capindepend
mechan
natur
virus
evolv
varieti
mechan
overcom
cap
restrict
virus
replic
within
nucleu
includ
dna
virus
retrovirus
use
host
cap
machineri
provid
primari
mean
protect
mrna
restrict
decroli
et
al
similarli
viral
famili
includ
orthomyxovirus
arenavirus
bunyavirus
employ
cap
snatch
excis
cap
structur
earli
host
rna
incorpor
nascent
viral
rna
final
mani
viral
famili
encod
cap
machineri
either
mimic
sequenti
eukaryot
approach
altern
approach
effect
maintain
translat
block
aspect
host
immun
recognit
exampl
later
approach
includ
vpglike
viral
protein
mimic
cap
structur
like
picornavirus
calicivirus
bind
viral
rna
act
cap
decroli
et
al
similarli
rna
secondari
structur
includ
intern
ribosom
entri
site
ire
element
permit
translat
viral
rna
may
offer
minor
protect
host
recognit
hyde
et
al
importantli
signific
portion
virus
encod
viral
cap
protein
directli
copi
host
machineri
make
indistinguish
host
mrna
neutral
import
barrier
viral
infect
coronavirus
seri
highli
conserv
nonstructur
protein
nsp
identifi
cap
viral
rna
detail
report
identifi
predict
role
chen
et
al
recent
complex
chen
et
al
debarnot
et
al
decroli
et
al
decroli
et
al
lugari
et
al
cap
cov
rna
similar
host
process
cap
believ
initi
rna
phosphatas
remov
phosphat
group
nascent
mrna
fig
cov
process
attribut
helicasentpas
although
yet
confirm
experiment
examin
fig
snijder
et
al
thereaft
undetermin
host
viral
guanyli
transferas
gtase
mediat
cleavag
gtp
gmp
coval
attach
diphosph
link
mrna
fig
next
samdepend
mtase
facilit
addit
methyl
group
guanosin
produc
viral
mrna
structur
fig
follow
step
viral
rna
effect
protect
rigi
recognit
free
triphosph
howev
absent
viral
mrna
still
trigger
sensor
ifit
effector
fig
mrna
cap
cov
complet
samdepend
ensur
format
protect
structur
prevent
recognit
either
ifit
protein
fig
final
complex
finish
cov
cap
process
permit
viral
infect
reduc
host
recognit
cov
belong
rrmjfibrillarin
superfamili
ribos
conserv
number
host
cellular
homologu
well
viral
ortholog
flavivirus
alphavirus
nidovirus
feder
et
al
famili
protein
catalyz
transfer
sadenosylmethionin
sam
methyl
group
methyl
acceptor
reli
conserv
kdke
tetrad
within
substrat
bind
pocket
activ
substitut
three
residu
kdk
result
ablat
catalyt
activ
feder
et
al
addit
tetrad
canon
member
enzym
famili
includ
catechol
omtas
maintain
conserv
structur
motif
sevenstrand
bsheet
flank
three
alpha
helic
side
constitut
acceptor
substrat
sambind
domain
martin
mcmillan
structur
catalyt
element
requir
samdepend
mtase
activ
cov
requir
viral
cofactor
distinguish
canon
famili
member
earli
comput
studi
predict
snijder
et
al
von
grotthuss
et
al
subsequ
work
confirm
low
present
activ
felin
cov
fcov
decroli
et
al
howev
recombin
sarscov
fail
replic
similar
activ
despit
noteworthi
homolog
fcov
examin
yeasttwo
hybrid
screen
later
reveal
strong
interact
suggest
possibl
role
cap
pan
et
al
work
demonstr
coexpress
permit
sarscov
activ
presenc
alreadi
cap
rna
similarli
coexpress
permit
captur
purifi
crystal
structur
unstabl
alon
base
structur
author
postul
absenc
two
flank
alpha
helic
result
less
stabl
cov
canon
famili
member
addit
potenti
allevi
instabl
permit
activ
occur
addit
structur
biochem
analysi
suggest
bind
within
region
provid
support
sambind
well
extend
rna
bind
groov
complex
chen
et
al
overal
data
demonstr
complex
interact
requir
stabil
activ
amino
acid
sequenc
highli
conserv
across
entir
cov
famili
suggest
similar
structur
domain
function
activ
conserv
illustr
structur
similar
sarscov
merscov
complex
fig
indic
mutat
ablat
alter
activ
would
conserv
across
entir
viral
famili
result
similar
phenotyp
mutant
therefor
therapeut
treatment
target
activ
function
may
prove
effect
previou
strain
like
sarscov
hcov
well
emerg
virus
like
merscov
pedv
initi
attempt
alter
function
focus
delet
conserv
kdke
tetrad
chen
et
al
delet
code
sequenc
block
rna
synthesi
similarli
delet
stream
compon
ntermin
zinc
bind
domain
also
ablat
viral
replic
rna
synthesi
almazan
et
al
howev
mutat
within
conserv
kdke
tetrad
result
sever
attenu
partial
viabl
mutant
viru
addit
temperatur
sensit
mutant
mous
hepat
viru
mhv
establish
role
synthesi
stabil
posit
strand
synthesi
sawicki
et
al
togeth
earli
studi
impli
critic
role
cov
life
cycl
howev
result
may
influenc
underli
immun
respons
captur
cell
cultur
system
subsequ
attempt
hcov
mhv
sarscov
abl
gener
mutant
reduc
ablat
activ
retain
robust
viral
replic
vitro
zust
et
al
substitut
aspart
acid
alanin
within
kdke
motif
hcov
result
ablat
activ
importantli
mutant
attenu
fibroblast
multistep
growth
curv
induc
type
ifn
macrophag
sensit
pretreat
wt
zust
et
al
howev
mutat
mhv
result
result
minim
attenu
murin
fibroblast
robust
replic
deficit
increas
type
ifn
induct
macrophag
suggest
cell
type
specif
contribut
attenu
notabl
mutat
target
put
bind
site
maintain
partial
activ
reduc
immun
induct
minim
replic
attenu
macrophag
compar
mutant
overal
data
suggest
activ
requir
effici
replic
certain
immun
compet
cell
sarscov
mutat
also
target
conserv
kdke
motif
focus
trio
requir
catalyt
activ
sarscov
mutant
gener
singl
amino
acid
chang
three
mutant
virus
viabl
replic
defect
vero
cell
contrast
previou
delet
studi
bhk
cell
almazan
et
al
underli
innat
immun
may
account
differ
three
sarscov
mutant
attenu
immun
compet
cell
multistep
replic
cycl
moi
sarscov
mutant
least
attenu
cell
character
vivo
demonstr
robust
attenu
late
time
later
regard
weight
loss
viral
lung
titer
lung
histolog
breath
function
notabl
sarscov
attenu
delay
vitro
vivo
suggest
initi
infect
fail
stimul
robust
immun
respons
wt
display
increas
type
ifn
sensit
similar
mutant
mhv
zust
et
al
sarscov
mutant
viru
fail
induc
type
ifn
either
vitro
vivo
similarli
analysi
known
interferonstimul
gene
includ
found
signific
chang
induct
magnitud
kinet
follow
challeng
compar
wt
fig
globabl
data
indic
sarscov
mutant
attenu
vitro
vivo
immun
respons
induc
host
play
critic
role
attenu
differ
mutant
across
viral
famili
may
explain
baselin
immun
respons
target
cell
may
higher
macrophag
less
robust
other
fibroblast
epitheli
cell
target
kdke
catalyt
tetrad
main
approach
ablat
activ
varieti
cov
sever
approach
may
also
effect
knock
activ
mention
previous
complex
bind
cap
rna
thu
permit
activ
therefor
mutat
activ
also
expect
ablat
may
captur
similar
phenotyp
outcom
addit
recent
effort
character
residu
requir
interact
also
provid
anoth
mean
target
function
prior
work
demonstr
alanin
replac
central
core
amino
acid
mhv
result
lethal
phenotyp
donaldson
et
al
mutat
track
within
interfac
complex
thu
may
alter
ablat
function
lugari
et
al
approach
includ
alter
substrat
bind
site
take
advantag
temperatur
sensit
mutant
repres
novel
mean
target
diminish
activ
cov
famili
virus
sensit
type
ifn
hallmark
mutant
across
cov
famili
hcov
mhv
mutant
encod
substitut
respect
infect
also
result
augment
type
ifn
product
attenu
macrophag
zust
et
al
contrast
mutat
sarscov
result
ablat
activ
ifn
sensit
surprisingli
infect
augment
type
ifn
induct
rel
wt
viru
fact
suggest
despit
produc
high
level
recogniz
nonself
rna
sarscov
abl
control
type
ifn
induct
pathway
illustr
point
mice
augment
viral
replic
fail
restor
virul
defici
sarscov
similarli
restor
wt
level
mutat
mhv
result
robust
replic
within
liver
spleen
mice
zust
et
al
togeth
data
indic
type
ifn
play
critic
role
attenu
primarili
mediat
addit
host
immun
respons
contrast
type
ifn
defici
absenc
result
robust
restor
cov
omtas
mutant
studi
murin
macrophag
demonstr
absent
mhv
mutant
restor
viral
replic
reduc
nuclear
local
zust
et
al
sensit
type
ifn
maintain
result
suggest
absenc
sensor
molecul
result
reduc
ifn
induct
zust
et
al
howev
mice
fail
restor
replic
mhv
partial
restor
bind
mutant
mhv
complement
defici
replic
mhv
restor
level
vivo
suggest
pathway
contribut
attenu
mhv
mutant
contrast
sarscov
mutant
found
restor
virul
mice
term
weight
loss
histolog
breath
function
discrep
like
explain
differ
cell
tropism
sarscov
limit
express
cell
within
lung
contrast
mhv
infect
varieti
immun
compet
cell
like
result
robust
system
respons
importantli
absenc
restor
sarscov
omtas
mutant
vivo
evid
exist
suggest
play
effector
role
knockdown
studi
util
shrna
indic
augment
replic
sarscov
mutant
absenc
contrast
ifit
famili
result
fig
result
suggest
function
primari
recognit
cov
omtas
mutant
initi
interferonstimul
gene
cascad
lead
attenu
replic
vitro
vivo
type
ifn
defici
led
restor
cov
mutant
neither
immun
compon
provid
direct
effector
function
instead
host
respons
requir
activ
ifit
famili
protein
mediat
attenu
cov
mutant
mutant
mhv
hcov
absenc
result
restor
replic
rel
wt
control
vitro
habjan
et
al
zust
et
al
similar
result
seen
sarscov
knockdown
howev
replic
augment
mice
mhv
remain
significantli
attenu
rel
wt
mhv
habjan
et
al
result
indic
ifit
restrict
type
ifn
induct
via
contribut
attenu
mhv
mutant
contrast
sarscov
mutant
restor
near
wt
level
mice
term
viral
replic
weight
loss
breath
function
defici
result
robust
infect
mutant
modest
augment
wt
sarscov
result
consist
restor
virul
observ
wnv
mutant
mice
daffi
et
al
indic
mediat
primari
attenu
sarscov
mutant
date
neither
cov
mutant
test
mice
display
increas
sensit
neurotrop
virus
includ
wildtyp
mhv
vsv
butchi
et
al
fensterl
et
al
similar
defici
differ
cell
type
tissu
tropism
mhv
sarscov
like
contribut
differenti
mutant
restor
defici
host
robust
attenu
cov
mutant
highlight
import
specif
aspect
host
innat
immun
respons
limit
viru
infect
absenc
type
ifn
induct
subsequ
isg
effector
respons
ifit
famili
necessari
compon
restor
cov
mutant
notabl
presenc
function
viral
antagonist
render
innat
immun
pathway
ineffect
wt
virus
note
minim
augment
diseas
ko
mice
frieman
et
al
habjan
et
al
menacheri
et
al
result
also
suggest
rapid
robust
innat
mediat
attenu
observ
cov
mutant
may
preclud
necess
adapt
immun
respons
clearanc
prior
work
demonstr
requir
b
tcell
clearanc
wt
sarscov
mutant
graham
et
al
sheahan
et
al
presenc
function
might
suffici
clear
sarscov
without
addit
adapt
respons
test
theori
defici
mice
infect
either
wt
sarscov
sarscov
fig
result
demonstr
attenu
similar
regard
weight
loss
replic
sarscov
maintain
day
signific
differ
rel
wt
sarscov
togeth
result
indic
despit
innat
mediat
attenu
sarscov
mutant
still
requir
adapt
immun
respons
steril
immun
clearanc
identifi
host
process
mediat
mutant
attenu
possibl
exist
leverag
knowledg
develop
therapeut
treatment
option
human
diseas
standard
treatment
target
essenti
viral
process
like
viral
proteas
replic
complex
format
approach
impair
aspect
viral
infect
improv
efficaci
host
immun
respons
target
disrupt
activ
viral
mrna
becom
suscept
activ
ifit
famili
member
attenu
viral
infect
natur
innat
immun
respons
importantli
broad
conserv
cov
well
number
viral
famili
provid
broadli
applic
approach
ideal
target
current
emerg
viral
infect
mind
vaccin
drug
treatment
approach
conceiv
target
activ
cov
emerg
viral
infect
employ
mutant
live
attenu
vaccin
platform
prove
effect
develop
vaccin
strategi
varieti
viral
famili
sever
flavivirus
includ
west
nile
dengu
japanes
enceph
virus
util
mutat
activ
domain
attenu
protect
anim
lethal
challeng
dong
et
al
zust
et
al
similar
vaccin
approach
recent
describ
paramyxovirus
includ
human
metapneumoviru
target
l
protein
mediat
activ
addit
recent
work
venezuelan
equin
enceph
viru
vee
reveal
singl
nucleotid
mutat
vaccin
strain
ablat
rna
structur
mimick
allow
recognit
viral
rna
hyde
et
al
broad
efficaci
approach
across
varieti
viral
famili
lend
credenc
applic
cov
emerg
virus
employ
overcom
host
immun
respons
et
al
parallel
success
found
rna
viru
vaccin
mutant
sarscov
prove
effect
live
attenu
vaccin
platform
young
suscept
balbc
mice
week
old
inocul
sarscov
pb
mock
control
follow
challeng
lethal
dose
mouseadapt
sarscov
mock
vaccin
anim
endur
rapid
weight
loss
death
contrast
vaccin
anim
present
clinic
sign
diseas
surviv
lethal
challeng
importantli
plaqu
reduct
neutral
titer
indic
high
level
protect
antibodi
produc
follow
vaccin
valu
repres
improv
live
attenu
platform
fett
et
al
graham
et
al
support
idea
robust
replic
induc
earli
infect
may
improv
overal
immun
perform
fett
et
al
menacheri
et
al
altern
augment
ifn
induct
via
may
result
greater
skew
thu
improv
qualiti
protect
adapt
respons
support
idea
defici
report
alter
earli
inflammatori
respons
lung
follow
sendai
viru
infect
kim
et
al
decreas
neutrophil
increas
altern
activ
macrophag
popul
indic
alter
tcell
composit
may
impact
immun
memori
respons
page
et
al
test
requir
result
suggest
target
activ
via
vaccin
may
serv
dual
role
attenu
viru
improv
overal
immun
respons
initi
studi
promis
sever
signific
question
remain
address
regard
efficaci
util
vaccin
platform
first
among
abil
mutant
protect
age
anim
date
multipl
vaccin
platform
fail
caus
immun
induc
patholog
age
popul
live
attenu
sarscov
platform
greater
efficaci
boll
et
al
sheahan
et
al
protect
paramet
must
explor
context
senesc
host
vaccin
move
forward
addit
mutat
maintain
tissu
cultur
studi
requir
assess
possibl
revers
two
nucleotid
chang
vivo
previous
describ
graham
et
al
result
may
indic
need
gener
evalu
revers
proof
mutant
employ
either
three
nucleotid
chang
multipl
mutat
within
kdke
motif
final
like
vaccin
platform
vaccin
must
evalu
efficaci
heterolog
challeng
potenti
emerg
sarslik
cov
strain
includ
newli
discov
bat
strain
ge
et
al
et
al
despit
question
util
mutat
basi
live
attenu
cov
platform
great
promis
sarscov
emerg
virus
like
merscov
pedv
addit
vaccin
platform
effort
impair
activ
context
normal
wildtyp
infect
may
also
provid
effect
treatment
option
year
number
small
molecul
identifi
abil
inhibit
activ
cov
includ
sadenosyllhomocystein
sinefungin
aurintricarboxyl
acid
ata
decroli
et
al
et
al
molecul
believ
interfer
substrat
bind
effect
ablat
activ
given
robust
attenu
mutant
find
provid
mechanist
explan
ata
inhibit
sarscov
replic
previous
describ
et
al
contrast
sinefungin
pretreat
alon
prove
ineffect
significantli
reduc
sarscov
replic
fig
howev
context
type
ifn
induct
addit
sinefungin
improv
overal
inhibit
collect
data
suggest
inhibit
use
cov
treatment
requir
activ
isg
respons
efficaci
notabl
target
sambind
site
would
also
expect
work
viral
encod
provid
broad
base
antivir
therapeut
howev
impact
host
activ
may
induc
cytotox
effect
limit
util
overal
data
argu
target
via
sambind
site
remain
viabl
treatment
approach
requir
refin
test
addit
target
activ
site
approach
exploit
indirect
factor
necessari
activ
highlight
earlier
requir
bind
stabil
activ
therefor
drug
interfer
interact
may
prove
effect
treatment
strategi
sar
cov
illustr
point
two
short
peptid
deriv
interact
domain
sarscov
shown
ablat
activ
ke
et
al
invers
approach
design
peptid
base
bind
domain
may
also
provid
addit
avenu
therapi
case
disrupt
interact
attenu
wildtyp
viru
robust
type
ifnisg
respons
induc
similarli
sequenti
natur
cov
cap
fig
requir
recognit
upstream
modif
activ
therefor
disrupt
element
cap
via
cov
mrna
process
also
ablat
activ
thu
render
enhanc
suscept
cov
specif
approach
potenti
significantli
impact
viral
infect
minim
toxic
concern
compar
approach
target
activ
site
importantli
drug
approach
outlin
requir
induct
host
isg
respons
efficaci
may
vari
greatli
depend
ifn
antagonist
encod
specif
cov
question
togeth
studi
defin
critic
element
illustr
import
activ
success
coronaviru
infect
absenc
function
sarscov
hcov
mhv
infect
significantli
attenu
vitro
vivo
deficit
mediat
increas
recognit
viral
rna
host
sensor
molecul
well
effector
respons
ifit
famili
isg
understand
precis
viralhost
interact
permit
develop
novel
therapeut
impair
viru
also
increas
efficaci
exist
host
immun
respons
contrast
method
target
viral
specif
factor
like
replic
fidel
structur
protein
function
approach
broad
applic
potenti
cov
viral
famili
employ
approach
cap
viral
rna
importantli
continu
threat
viral
emerg
highlight
merscov
pedv
past
year
target
highli
conserv
activ
provid
therapeut
approach
applic
novel
cov
signific
research
question
remain
understand
target
activ
repres
import
avenu
treat
current
futur
cov
mediat
diseas
b
triphosph
cleavag
initi
first
step
mrna
cap
predict
mediat
cov
helicasertpas
c
guanyli
transferas
gtase
cleav
gtp
gmp
mediat
attach
diphosph
link
nascent
rna
gtase
yet
identifi
cov
cap
process
cov
sam
depend
methyltransferas
mtase
methyl
guanosin
result
structur
e
structur
protect
rigi
recognit
still
stimul
ifit
protein
via
unprotect
recogn
bind
cov
rna
result
methyl
f
viral
mrna
fail
induc
either
mda
ifit
protein
permit
robust
viral
replic
absenc
innat
immun
respons
conserv
cov
overlay
structur
sarscov
black
emerg
merscov
gray
conserv
kdke
motif
repres
inset
sarscov
primari
color
merscov
pastel
color
also
shown
requir
scaffold
sarscov
pink
merscov
orang
homolog
model
creat
use
model
maxplanck
institut
bioinformat
toolkit
known
crystal
structur
complex
rcsb
protein
data
bank
use
templat
structur
chen
et
al
homolog
model
manipul
use
macpymol
ifit
protein
provid
effector
function
mutant
virus
vero
cell
express
shrna
describ
target
blue
red
green
two
construct
shrna
control
black
pretreat
pbl
laboratori
infect
sarscov
b
pvalu
base
student
ttest
mark
indic
adapt
immun
respons
still
requir
clearanc
tenweekold
mice
defici
adapt
immun
infect
either
sarscov
black
red
weight
loss
b
viral
titer
result
demonstr
continu
attenu
fail
clearanc
either
viru
ten
day
postinfect
studi
carri
accord
recommend
care
use
anim
offic
laboratori
anim
welfar
olaw
nih
unc
institut
anim
care
use
committe
iacuc
unc
permit
number
approv
anim
studi
protocol
iacuc
follow
experi
